Regencell Bioscience Holdings Limited RGC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.42M | 8.35M | 6.28M | 4.55M | 2.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.72M | 9.43M | 7.13M | 5.45M | 3.77M |
| Operating Income | -11.72M | -9.43M | -7.13M | -5.45M | -3.77M |
| Income Before Tax | -11.70M | -9.38M | -7.05M | -5.32M | -3.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.70 | -9.38 | -7.05 | -5.32 | -3.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.70M | -9.38M | -7.05M | -5.32M | -3.58M |
| EBIT | -11.72M | -9.43M | -7.13M | -5.45M | -3.77M |
| EBITDA | -11.64M | -9.35M | -7.07M | -5.38M | -3.69M |
| EPS Basic | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B |
| Average Diluted Shares Outstanding | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |